clinical trial

[Lancet Haematology] Scientists reported the results of a prospective, single-arm, Phase II clinical trial done at the University Medical Center Utrecht and the Princess Máxima Center for Pediatric Oncology to investigate individualized dosing of anti-thymocyte globulin for unrelated allogeneic HSC transplantation in pediatric patients.

[American Journal of Hematology] A single-arm exploratory clinical trial is the first to evaluate the safety and efficacy of sequential anti-CD19 and anti-BCMA CAR-T cell infusion, followed by lenalidomide maintenance after autologous stem-cell transplantation in ten high-risk newly diagnosed multiple myeloma patients.

[LAVA Therapeutics] LAVA Therapeutics announced dosing of the first patient in the company’s Phase I/IIa clinical trial of LAVA-1207 in patients with metastatic CRPC.

[Cancer Science] Scientists investigated the effect of PMD-026 on YB-1/AR signaling and its antitumor effect in prostate cancer in vitro and in vivo and demonstrated an excellent antitumor effect of the novel ribosomal S6 kinase inhibitor PMD-026 and the combination effect with the antiandrogen enzalutamide in CRPC.

[NorthSea Therapeutics B.V.] NorthSea Therapeutics B.V. announced it has initiated a Phase I study with SEFA-6179 in adult subjects, targeting the initial orphan indication of the treatment of intestinal failure associated liver disease.

[Veru, Inc.] Veru, Inc. announced that it has entered into a clinical trial collaboration and supply agreement with Eli Lilly and company which will evaluate the efficacy and safety of enobosarm in combination with Lilly’s abemaciclib as a second line therapy in the treatment of AR+ER+HER2- metastatic breast cancer